Prescriptions for Ozempic soar

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

The Washington Post · 1d

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Fox Business on MSN · 1d

Pfizer scraps twice-daily weight loss pill danuglipron after study shows ‘high rates’ of adverse side effects

Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.

CNBC on MSN · 1d

Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops

Pfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped obesity drugs. Pfizer's move to drop two obesity drug candidates in the last year demonstrates how difficult it is to develop an effective,

Reuters · 1d

Pfizer drops twice-daily version of obesity pill over side effects

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting,

MarketWatch on MSN · 1d

Pfizer’s stock falls 6% after halting trial of obesity drug due to side effects

Pfizer Inc.’s stock tumbled 6% Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects.

YAHOO!News · 20h

Pfizer Cancels New Weight Loss Pill After Patients Experience Serious Side Effects

Pfizer's new experimental weight-loss pill worked in achieving its stated goal — but with that weight loss came some pretty gnarly-sounding side effects. In a press release, the pharmaceutical giant said that it was discontinuing clinical trials for danuglipron,

Reuters on MSN · 1d

UPDATE 1-Pfizer drops plan to study twice-daily obesity pill in late-stage studies

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates of side effects such as nausea and vomiting.

MarketWatch on MSN · 1d

Pfizer’s stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation

MARKET PULSE Pfizer Inc.’s stock fell 4% premarket Friday, after the company said it’s not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adults with obesity and type 2 diabetes after high rates of adverse events in the Phase 2b trial.

Reuters2d

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...

3mon

Wegovy weight-loss drugmaker sees profits soar

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

The Motley Fool1mon

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's. Both stocks could be winners for ...

Futurism2mon

Snack Food CEO Vows to Battle Ozempic

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Healthline18d

Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy

Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...

Medindia17d

Medications and their Potential to Cause Increase 'Throat sore'

This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please ...

BioPharma Dive1d

European regulators want to know more about the risks of GLP-1 drugs

The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.

The Guardian1mon

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending on Bing